CTIC - シ―ティ―アイ・バイオファ―マ (CTI BioPharma Corp.) シ―ティ―アイ・バイオファ―マ

 CTICのチャート


 CTICの企業情報

symbol CTIC
会社名 CTI BioPharma Corp (シ―ティ―アイ・バイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 CTIバイオファーマ(CTI BioPharma Corp. )(旧称:Cell Therapeutics Inc.)は癌を治療する毒性の少ない方法の取得・開発・商品化に焦点を当てるバイオ医薬品会社。同社は満たされていない医療ニーズのある血液関連癌向けの治療に力を集中する。同社は主に再発乗算または難治性の積極的な非ホジキンリンパ腫(NHL)のために、欧州連合でPIXUVRI(ピクサントロン)の商品化に従事する他、骨髄線維症の治療用pacritinibの第三相臨床試験を実行する。PIXUVRIは新規アザ・アントラセンジオン誘導体であり、構造的にアントラサイクリン及びアントラセンジオンに関連するが、心毒性作用の同じレベルに関連すると表示されない。   シ―ティ―アイ・バイオファ―マは、米国のバイオ医薬品会社。癌治療法の取得、開発、商業化に従事する。欧州地方で非ホジキンリンパ腫治療の「PIXUVRI(ピクサントロン)」を商品化することに焦点を当てる。血液関連癌のスペクトルをカバ―する新たな治療標的を当てるほか癌と共に生きる人々のための治療選択肢の開発も展開する。   
本社所在地 3101 Western Avenue Suite 600 Seattle WA 98121 USA
代表者氏名
代表者役職名
電話番号 +1 206-282-7100
設立年月日 33482
市場名 NASDAQ Small Cap
ipoyear 1997年
従業員数 149人
url www.celltherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/ctic
adr_tso
EBITDA EBITDA(百万ドル) -43.17000
終値(lastsale) 2.05
時価総額(marketcap) 118877294.2
時価総額 時価総額(百万ドル) 118.87730
売上高 売上高(百万ドル) 13.25700
企業価値(EV) 企業価値(EV)(百万ドル) 40.31630
当期純利益 当期純利益(百万ドル) -41.67700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 CTI BioPharma Corp revenues decreased 52% to $11.1M. Net loss applicable to common stockholders decreased 18% to $15.4M. Revenues reflect License and contract revenue decrease of 49% to $11.1M Product sales net decrease from $1M to $0K. Lower net loss reflects Other selling general decrease of 47% to $8.4M (expense) Other non-operating income (expense) increase from $30K (expense) to $4.7M (income).

 CTICのテクニカル分析


 CTICのニュース

   CTI BioPharma to Present at The JMP Securities Hematology Summit on Tuesday, Dec. 15  2020/12/08 12:00:00 PR Newswire
SEATTLE, Dec. 8, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at The JMP Securities Hematology Summit at 3:00 p.m. EST. The conference will be held in a virtual meeting format. Presentation details: Event: The…
   CTI BioPharma Reports Third Quarter 2020 Financial Results  2020/11/10 21:05:00 PR Newswire
SEATTLE, Nov. 10, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter and nine months ended September 30, 2020. "This past quarter we made significant progress in our pacritinib development program. We recently announced the…
   CTI BioPharma to Report Third Quarter 2020 Financial Results on November 10, 2020  2020/11/02 21:05:00 PR Newswire
SEATTLE, Nov. 2, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2020 financial results on Tuesday, November 10, 2020, after the close of the U.S. financial markets. Following the announcement,…
   CTI BioPharma (NASDAQ:CTIC) Coverage Initiated by Analysts at Brookline Capital Management  2020/10/24 12:38:46 Transcript Daily
Brookline Capital Management began coverage on shares of CTI BioPharma (NASDAQ:CTIC) in a research note issued to investors on Friday, The Fly reports. The firm issued a buy rating and a $7.00 price target on the biopharmaceutical company’s stock. Several other research analysts have also recently weighed in on the company. Lake Street Capital restated […]
   CTI BioPharma Initiates Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia  2020/10/13 11:00:00 PR Newswire
SEATTLE, Oct. 13, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has commenced a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration ("FDA" or "the Agency") seeking approval of pacritinib as a treatment for myelofibrosis…
   CTI BioPharma to Report Third Quarter 2020 Financial Results on November 10, 2020  2020/11/02 21:05:00 PR Newswire
SEATTLE, Nov. 2, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2020 financial results on Tuesday, November 10, 2020, after the close of the U.S. financial markets. Following the announcement,…
   CTI BioPharma (NASDAQ:CTIC) Coverage Initiated by Analysts at Brookline Capital Management  2020/10/24 12:38:46 Transcript Daily
Brookline Capital Management began coverage on shares of CTI BioPharma (NASDAQ:CTIC) in a research note issued to investors on Friday, The Fly reports. The firm issued a buy rating and a $7.00 price target on the biopharmaceutical company’s stock. Several other research analysts have also recently weighed in on the company. Lake Street Capital restated […]
   CTI BioPharma Initiates Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia  2020/10/13 11:00:00 PR Newswire
SEATTLE, Oct. 13, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has commenced a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration ("FDA" or "the Agency") seeking approval of pacritinib as a treatment for myelofibrosis…
   The Daily Biotech Pulse: Bristol-Myers Squibb's Lung Cancer Readout, Positive News From Masimo, Integra Lifesciences  2020/10/07 11:30:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) 10X Genomics Inc (NASDAQ: TXG ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) CareDx Inc (NASDAQ: CDNA ) Castle Biosciences Inc (NASDAQ: CSTL ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CTI BioPharma Corp (NASDAQ: CTIC ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) Inspire Medical Systems Inc (NYSE: INSP ) InVitae Corp (NYSE: NVTA ) Kura Oncology Inc (NASDAQ: KURA ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Prelude Therapeutics Inc (NASDAQ: PRLD ) ProPhase Labs Inc (NASDAQ: PRPH ) Qiagen NV (NYSE: QGEN ) Repligen Corporation (NASDAQ: RGEN ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Twist Bioscience Corp (NASDAQ: TWST ) Vericel Corp (NASDAQ: VCEL ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 6) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) (reacted to negative results for a mid-stage study of lenabasum in cystic fibrosis patients) Dyne Therapeutics Inc (NASDAQ: DYN ) Outset Medical Inc (NASDAQ: OM ) Teligent Inc (NASDAQ: TLGT ) Stocks In Focus Integra LifeSciences' Preliminary Q3 Revenues Exceed Estimate Medtech company Integra Lifesciences Holdings Corp (NASDAQ: IART ) preannounced third-quarter results, expecting revenues of $368 million to $370 million, down about 2.7%, but exceeding the company's guidance provided at …
   The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation  2020/10/06 12:24:11 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) 10X Genomics Inc (NASDAQ: TXG ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) argenx SE – ADR (NASDAQ: ARGX ) (presented positive new data from a Phase 3 trial evaluating efgartigimod in patients with generalized myasthenia gravis) Ascendis Pharma A/S (NASDAQ: ASND ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) C4 Therapeutics, Inc. (NASDAQ: CCCC ) (went public Friday) Castle Biosciences Inc (NASDAQ: CSTL ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CTI BioPharma Corp (NASDAQ: CTIC ) Cytokinetics, Inc. (NASDAQ: CYTK ) (reacted to presentations at the Heart Failure Society of America virtual meeting) Eidos Therapeutics Inc (NASDAQ: EIDX ) - announced a deal to be bought by BridgeBio Pharma Inc (NASDAQ: BBIO ) EXACT Sciences Corporation (NASDAQ: EXAS ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Kura Oncology Inc (NASDAQ: KURA ) LifeSci Acquisition Corp (NASDAQ: LSAC ) Myokardia Inc (NASDAQ: MYOK ) - announced a deal to be bought by Bristol-Myers Squibb Co (NYSE: BMY ) for $13.
   The Daily Biotech Pulse: Bristol-Myers Squibb's Lung Cancer Readout, Positive News From Masimo, Integra Lifesciences  2020/10/07 11:30:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) 10X Genomics Inc (NASDAQ: TXG ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) CareDx Inc (NASDAQ: CDNA ) Castle Biosciences Inc (NASDAQ: CSTL ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CTI BioPharma Corp (NASDAQ: CTIC ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) Inspire Medical Systems Inc (NYSE: INSP ) InVitae Corp (NYSE: NVTA ) Kura Oncology Inc (NASDAQ: KURA ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Prelude Therapeutics Inc (NASDAQ: PRLD ) ProPhase Labs Inc (NASDAQ: PRPH ) Qiagen NV (NYSE: QGEN ) Repligen Corporation (NASDAQ: RGEN ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Twist Bioscience Corp (NASDAQ: TWST ) Vericel Corp (NASDAQ: VCEL ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 6) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) (reacted to negative results for a mid-stage study of lenabasum in cystic fibrosis patients) Dyne Therapeutics Inc (NASDAQ: DYN ) Outset Medical Inc (NASDAQ: OM ) Teligent Inc (NASDAQ: TLGT ) Stocks In Focus Integra LifeSciences' Preliminary Q3 Revenues Exceed Estimate Medtech company Integra Lifesciences Holdings Corp (NASDAQ: IART ) preannounced third-quarter results, expecting revenues of $368 million to $370 million, down about 2.7%, but exceeding the company's guidance provided at …
   The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation  2020/10/06 12:24:11 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) 10X Genomics Inc (NASDAQ: TXG ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) argenx SE – ADR (NASDAQ: ARGX ) (presented positive new data from a Phase 3 trial evaluating efgartigimod in patients with generalized myasthenia gravis) Ascendis Pharma A/S (NASDAQ: ASND ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) C4 Therapeutics, Inc. (NASDAQ: CCCC ) (went public Friday) Castle Biosciences Inc (NASDAQ: CSTL ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CTI BioPharma Corp (NASDAQ: CTIC ) Cytokinetics, Inc. (NASDAQ: CYTK ) (reacted to presentations at the Heart Failure Society of America virtual meeting) Eidos Therapeutics Inc (NASDAQ: EIDX ) - announced a deal to be bought by BridgeBio Pharma Inc (NASDAQ: BBIO ) EXACT Sciences Corporation (NASDAQ: EXAS ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Kura Oncology Inc (NASDAQ: KURA ) LifeSci Acquisition Corp (NASDAQ: LSAC ) Myokardia Inc (NASDAQ: MYOK ) - announced a deal to be bought by Bristol-Myers Squibb Co (NYSE: BMY ) for $13.
   58 Biggest Movers From Friday  2020/10/05 08:32:53 Benzinga
Gainers Xtant Medical Holdings, Inc. (NYSE: XTNT ) shares climbed 91.4% to close at $1.57 on Friday after the company announced the closing of debt restructuring. American Renal Associates Holdings, Inc. (NYSE: ARA ) shares climbed 66.5% to close at $11.52 after the company reported an $11.50 per share cash offer from Nautic Partners. Nano-X Imaging Ltd. (NASDAQ: NNOX ) shares gained 56.2% to close at $37.44 after the company announced it will demonstrate its novel technology and medical imaging system at RSNA 2020, which is being held from November 29th to December 5th in Chicago. Westwater Resources, Inc. (NASDAQ: WWR ) surged 49.3% to close at $4.42. IDT Corporation (NYSE: IDT ) gained 39.1% to close at $9.57 after reporting higher earnings and sales for the fourth quarter. C4 Therapeutics, Inc. (NASDAQ: CCCC ) rose 34.2% to close at $25.49 after pricing its IPO at $19 per share. ProPhase Labs, Inc. (NASDAQ: PRPH ) surged 32.1% to close at $5.15. ProPhase Labs climbed 13% on Thursday after the company announced plans to explore the acquisition of one or more CLIA accredited labs suitable for COVID-19 and other testing.
   The Daily Biotech Pulse: Amag Spikes On Takeover Rumors, Zosano Wilts On Regulatory Setback, Pulmonx Makes Wall Street Debut  2020/10/01 12:18:26 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Annexon Inc (NASDAQ: ANNX ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cardiff Oncology Inc (NASDAQ: CRDF ) CareDx Inc (NASDAQ: CDNA ) CTI BioPharma Corp (NASDAQ: CTIC ) I-Mab ADR (NASDAQ: IMAB ) Insulet Corporation (NASDAQ: PODD ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kura Oncology Inc (NASDAQ: KURA ) LifeSci Acquisition Corp (NASDAQ: LSAC ) (the blank check company announced a business combination with oncology-focused Vincera Pharma) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PMV Pharmaceuticals Inc (NASDAQ: PMVP ) PPD Inc (NASDAQ: PPD ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Shockwave Medical Inc (NASDAQ: SWAV ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 30) Abeona Therapeutics Inc (NASDAQ: ABEO ) Alector Inc (NASDAQ: ALEC ) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Neos Therapeutics Inc (NASDAQ: NEOS ) Oncternal Therapeutics Inc (NASDAQ: ONCT ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) Pandion Therapeutics Inc (NASDAQ: PAND ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) Theravance Biopharma Inc (NASDAQ: TBPH ) Tricida Inc (NASDAQ: TCDA ) Stocks In Focus Amag Reportedly Pursued By Apollo's Covis Pharma AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) shares surged higher after a Bloomberg report said Apollo Management's Covis Pharma unit is in advanced talks to buy Amag.
   CTI BioPharma News: Why CTIC Stock Is Skyrocketing 104% Today  2020/09/30 19:31:22 InvestorPlace
CTI BioPharma (CTIC) news for Wednesday includes plans to submit a new drug application (NDA) sending CTIC stock soaring higher.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 シ―ティ―アイ・バイオファ―マ CTIC CTI BioPharma Corp.)

 twitter  (公式ツイッターやCEOツイッターなど)